Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506).

doi:10.1016/j.lungcan.2018.06.008

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506).

Lung cancer (Amsterdam, Netherlands) - 1 Sept 2018

Song Yong, Zhou Qing, Zhang Xin, Chen Gong-Yan, Zhong Dian-Sheng, Yu Zhuang, Yu Ping, Zhang Yi-Ping, Chen Jian-Hua, Hu Yi, Feng Guo-Sheng, Song Xia, Shi Qiang, Yang Lu Lu, Yao Luan Di, Zhan Lu Jing, Yang Fan, Wu Yi-Long

Abstract excerpt

OBJECTIVES: This study investigated factors associated with (i) the likelihood of receiving a gene aberration test and (ii) the choice of treatment between chemotherapy and targeted therapy in patients with non-small cell lung cancer (NSCLC) in China. MATERIALS AND METHODS: This cross-sectional study analyzed data previously extracted from the medical charts of patients with unresectable Stage IIIB/IV nonsquamous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Clinical Decision-Making

Share to Disease Management

Share to Health Care Surveys

Share to Molecular Targeted Therapy

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 30089597
DOI: 10.1016/j.lungcan.2018.06.008

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506).PMID 30089597Read ↗

A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).Semantic proximity Read ↗

Barries in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World-Evidence ScenarioSemantic proximity Read ↗

Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.Semantic proximity Read ↗

Real-World Molecular Testing and Treatment Patterns in Brazilian Patients with Newly Diagnosed Locally Advanced or Metastatic NSCLC.Semantic proximity Read ↗

Individualized treatment of NSCLC: from research to clinical practice.Semantic proximity Read ↗

[Prognostic Analysis of Patients with Advanced Non-small Cell Lung Cancer in Different Genotypes].Semantic proximity Read ↗

Molecular determinants of clinical outcomes for anaplastic lymphoma kinase-positive non-small cell lung cancer in Chinese patients: A retrospective study.Semantic proximity Read ↗

Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Exploratory analysis of gene aberrations and chemotherapy response: findings from a real-world database in Japan.Semantic proximity Read ↗

Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma.Semantic proximity Read ↗

Does the Waiting Period for Genetic Tests Affect the Prognosis in Chemotherapy-Treated de novo Metastatic Non-Small Cell Lung Cancer Patients without a Driver Mutation?Semantic proximity Read ↗

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.